drugset / Trial / NCT05319314
LYL273 for Patients With Relapsed or Refractory mCRC
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2028-06
- Completion
- 2032-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LYL273 | Cell therapy | — | Intravenous |